WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412469
CAS#: 104224-10-4
Description: CD270 is a biochemical
Hodoodo Cat#: H412469
Name: CD270
CAS#: 104224-10-4
Chemical Formula: C23H24O2S
Exact Mass: 364.15
Molecular Weight: 364.500
Elemental Analysis: C, 75.79; H, 6.64; O, 8.78; S, 8.80
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CD 270; CD-270; CD270
IUPAC/Chemical Name: 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzo[b]thiophene-6-carboxylic acid
InChi Key: VYBLDUKQAWIMMM-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H24O2S/c1-22(2)9-10-23(3,4)18-11-14(7-8-17(18)22)19-12-15-5-6-16(21(24)25)13-20(15)26-19/h5-8,11-13H,9-10H2,1-4H3,(H,24,25)
SMILES Code: CC1(CCC(C)(c2c1ccc(c(c3)sc4c3ccc(C(O)=O)c4)c2)C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 364.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Matesanz-Isabel J, Sintes J, Llinàs L, de Salort J, Lázaro A, Engel P. New B-cell CD molecules. Immunol Lett. 2011 Jan 30;134(2):104-12. doi: 10.1016/j.imlet.2010.09.019. Epub 2010 Oct 7. PMID: 20933010.
2: Wang S, Ljubimov AV, Jin L, Pfeffer K, Kronenberg M, Ghiasi H. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript. J Virol. 2018 Nov 27;92(24):e01451-18. doi: 10.1128/JVI.01451-18. PMID: 30282707; PMCID: PMC6258941.
3: Llinàs L, Lázaro A, de Salort J, Matesanz-Isabel J, Sintes J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett. 2011 Jan 30;134(2):113-21. doi: 10.1016/j.imlet.2010.10.009. Epub 2010 Oct 15. PMID: 20951740.
4: Shui JW, Kronenberg M. HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes. Gut Microbes. 2013 Mar- Apr;4(2):146-51. doi: 10.4161/gmic.23443. Epub 2013 Jan 18. PMID: 23333859; PMCID: PMC3595075.
5: Shui JW, Kronenberg M. HVEM is a TNF Receptor with Multiple Regulatory Roles in the Mucosal Immune System. Immune Netw. 2014 Apr;14(2):67-72. doi: 10.4110/in.2014.14.2.67. Epub 2014 Apr 21. PMID: 24851095; PMCID: PMC4022780.
6: Ramos-Medina R, Montes-Moreno S, Maestre L, Cañamero M, Rodriguez-Pinilla M, Lázaro A, Roncador G. Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunol Lett. 2011 Jan 30;134(2):150-6. doi: 10.1016/j.imlet.2010.10.007. Epub 2010 Oct 12. PMID: 20946916.
7: Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Sep;55(9):2085-92. doi: 10.3109/10428194.2013.867486. Epub 2014 Jan 24. PMID: 24289109.
8: Cabezón R, Sintes J, Llinàs L, Benitez-Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011 Jan 30;134(2):167-73. doi: 10.1016/j.imlet.2010.09.020. Epub 2010 Oct 7. PMID: 20933012.
9: Rodríguez-Bayona B, Ramos-Amaya A, Brieva JA. Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation. Immunol Lett. 2011 Jan 30;134(2):122-8. doi: 10.1016/j.imlet.2010.09.015. Epub 2010 Oct 13. PMID: 20923684.
10: Gazith J, Eustache J, Watts O, Cavey MT, Shroot B. An improved assay procedure and a new chemically stable ligand for cytosolic retinoic acid binding protein. Anal Biochem. 1988 Jun;171(2):238-47. doi: 10.1016/0003-2697(88)90481-2. PMID: 2841888.